Applications

1689 – Quantification of NT-proBNP in patients with systemic sclerosis, and in patients with diagnosed pulmonary arterial hypertension

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation Closed
  • Pre-MSAC consultation Closed
  • Outcome Partially supported

Application details

Reason for application

New MBS item.

Service or technology in this application

Measurement of NT-proBNP (also known as N-terminal pro-brain natriuretic peptide, N-terminal pro-B-type natriuretic peptide or N-terminal prohormone of brain natriuretic peptide) through a blood test. The blood test is intended to enable the early detection of systemic sclerosis related pulmonary arterial hypertension, and be used as a regular assessment of pulmonary arterial hypertension disease progression.

Type: Investigative technology

Medical condition this application addresses

Systemic sclerosis (scleroderma) is a multi-organ autoimmune disease characterised by vasculopathy (disease affecting blood vessels) and fibrosis (thickening and scarring of connective tissue). Patients with systemic sclerosis are at an increased risk of pulmonary arterial hypertension. Pulmonary arterial hypertension is characterised by increased pulmonary vascular resistance (resistance against blood flow), and may be idiopathic (arising from an unknown cause), or due to other underlying factors or disease associations such as connective tissue disease.

Consultation survey and deadlines

  • PASC consultation: Closed
  • MSAC consultation: Closed Friday 10 June 2022

Meetings to consider this application

  • PASC meeting: 9–10 December 2021
  • ESC meeting: 9–10 June 2022
  • MSAC meeting: 28–29 July 2022